#United States #Minneapolis #Bio-Techne #earnings report #fiscal quarter

Bio-Techne Corporation Reports Strong Financial Results for Q3 FY2025

Bio-Techne Corporation, listed on NASDAQ under the ticker TECH, recently unveiled its financial statistics for the third quarter ending March 31, 2025. Their results exhibited notable organic growth and highlighted several key performance indicators, reinforcing the company's strong position in the life sciences sector.

Highlights of Q3 FY2025

In the third quarter, Bio-Techne achieved a 6% increase in organic revenue which amounted to $316.2 million. In contrast, the reported revenue growth was 4%. This growth trajectory illustrates the company's resilient performance despite fluctuating market dynamics.

One noteworthy note is the GAAP earnings per share (EPS) which clocked at $0.14, a decline from $0.31 in the same quarter last year. However, when adjusted, EPS saw an increase, reaching $0.56, up from $0.48 year-over-year. This adjusted EPS emphasizes Bio-Techne's effective management strategies despite external pressures.

The Protein Sciences segment also showed robust figures, with a 7% organic growth rate and revenue reaching $227.7 million, a significant uptick from $214.6 million from the prior year. This growth was attributed to positive impacts from larger pharmaceutical partners, boosting their cell therapy and protein analysis instrumentation business.

In terms of profitability, Bio-Techne reported an adjusted operating margin of 34.9% compared to 33.0% in the previous year. This improvement was a result of dedicated profitability initiatives and robust volume leverage.

Insights from Company Leadership

President and CEO, Kim Kelderman, commented on the ongoing performance, stating, “Despite a dynamic macroenvironment, the Bio-Techne team once again executed at a high level and delivered strong third quarter results.” He further noted the positive trend in their pharma end market, showcasing the company’s strategic planning and execution abilities within its diverse portfolio.

Kelderman emphasized the significance of their geographic positioning and market segmentation, attributing the company's ability to navigate the current operational challenges to the strength of their leadership and robust portfolio developed over the last five decades.

Financial Health and Future Outlook

Bio-Techne's overall financial health remains positive as they maintain a well-balanced portfolio aiding scientific discoveries and diagnostic solutions. Their net sales totaled approximately $1.2 billion in fiscal 2024, indicating steady growth and a commitment to innovation within the research and clinical diagnostics communities.

With a commitment to enhancing operational efficiency, the outlook for Bio-Techne appears promising as they aim to sustain revenue growth and profitability ratios in subsequent quarters. The focus on research, product development, and integrating new technologies will likely propel them forward, adapting dynamically to industry changes while achieving robust financial performance.

Bio-Techne will conduct a conference call regarding these results on May 7, 2025. Interested parties can participate through a dial-in or access the live webcast via their official investor relations page. The continued encouragement of shareholder engagement underscores their commitment to transparency and fiscal responsibility.

In conclusion, Bio-Techne’s Q3 FY2025 results reflect a strong operational execution, clever management strategies, and a steadily growing market presence. As they continue navigating the complexities of the biotech landscape, the company's emphasis on innovation and quality solutions will be pivotal for sustained success.